Cancer Treatment

Urethral Cancer: Current Treatments and Future Progress

4 min read
Image of lungs

Urethral Cancer: Current Treatments and Future Progress

Introduction

Urethral cancer is a rare type of cancer that affects the urethra, the tube that carries urine from the bladder to the outside of the body. This type of cancer predominantly occurs in men, with only a small percentage of cases found in women. Urethral cancer can be categorized into two types: primary urethral cancer, which originates in the urethra, and secondary urethral cancer, which spreads from nearby organs such as the bladder or prostate. In this article, we will explore the epidemiology, diagnosis, and current treatment options for urethral cancer, as well as discuss some of the promising future drugs that are currently in late-stage clinical trials.

Epidemiology

Urethral cancer accounts for less than 1% of all cancer cases, making it a relatively rare condition. Men are more likely to develop urethral cancer compared to women, with the male-to-female ratio being approximately 4:1. The average age at diagnosis is around 70 years old. Exposure to certain risk factors, such as smoking, chronic inflammation of the urethra, and sexually transmitted infections, may increase the likelihood of developing urethral cancer. However, the exact cause of urethral cancer remains largely unknown.

Diagnosis

Early diagnosis of urethral cancer is crucial for effective treatment. Common symptoms of urethral cancer include blood in the urine, frequent urination, pain or burning during urination, and a lump or mass in the urethral area. If urethral cancer is suspected, a series of diagnostic tests may be performed, including a physical examination, urine analysis, imaging tests (such as ultrasound or CT scan), and a biopsy to confirm the presence of cancer cells.

Treatment

Treatment options for urethral cancer depend on several factors, including the stage and location of the cancer, as well as the overall health of the patient. The main treatment modalities for urethral cancer include surgery, radiation therapy, and chemotherapy. In early-stage urethral cancer, surgery is often the primary treatment method, aiming to remove the tumor and preserve as much of the unaffected urethra as possible. In more advanced cases, a combination of radiation therapy and chemotherapy may be recommended to shrink the tumor before surgery or as a palliative treatment to relieve symptoms.

Current Treatments

Several drugs are currently used in the treatment of urethral cancer. These include:

  • Gemcitabine and cisplatin: This combination chemotherapy regimen has shown promising results in treating advanced urethral cancer. It works by targeting cancer cells and inhibiting their growth.
  • Mitomycin C: This chemotherapy drug is commonly used in intravesical therapy, where it is directly instilled into the bladder to treat early-stage urethral cancer.
  • Fluorouracil (5-FU): 5-FU is another chemotherapy drug that can be used in the treatment of urethral cancer. It acts by interfering with the DNA synthesis process in cancer cells.
  • Immunotherapy: Immunotherapy drugs, such as pembrolizumab and nivolumab, have shown promise in treating certain types of advanced urethral cancer by boosting the body's immune response against cancer cells.

Promising Future Drugs in Clinical Trials

While the current treatments for urethral cancer have shown some success, there is ongoing research to develop more effective therapies. Several drugs are currently in late-stage clinical trials for the treatment of urethral cancer. These include:

  • Erdafitinib: Erdafitinib is a targeted therapy that inhibits specific genetic mutations found in some cases of urethral cancer. Clinical trials have shown promising results, leading to its potential approval for the treatment of advanced urethral cancer.
  • Mirvetuximab soravtansine: This antibody-drug conjugate specifically targets a protein called folate receptor alpha, which is often overexpressed in urethral cancer cells. Early clinical trials have shown positive response rates, making it a hopeful option for future treatment.
  • Enfortumab vedotin: Enfortumab vedotin is an antibody-drug conjugate that targets a protein called Nectin-4, which is frequently present in urethral cancer. Phase II clinical trials have demonstrated encouraging response rates and durable remission in patients with advanced urethral cancer.

Conclusion

Urethral cancer is a rare condition that predominantly affects men. Early diagnosis and timely treatment are crucial for improving outcomes. Currently, several drugs, including gemcitabine and cisplatin, mitomycin C, fluorouracil, and immunotherapy, are used in the treatment of urethral cancer. However, ongoing clinical trials offer hope for the development of more effective treatments, such as erdafitinib, mirvetuximab soravtansine, and enfortumab vedotin. As researchers continue to uncover new insights into the mechanisms of urethral cancer, the future looks promising for improved therapies and better outcomes for patients.